Key result
Clopidogrel resistance linked to ~18-fold higher recurrent cardiovascular events at 6 months after primary PCI.
Why the study?
Although clopidogrel reduces cardiovascular risk after coronary events and stenting, a substantial number of incidents continue to occur, and the impact of clopidogrel resistance on outcomes is unclear.
Does clopidogrel resistance increase the risk of recurrent cardiovascular events in STEMI patients undergoing primary PCI with stenting?
Cohort (n=60)
Does clopidogrel resistance increase the risk of recurrent cardiovascular events in STEMI patients undergoing primary PCI with stenting?
Clopidogrel resistance, present in up to 25% of STEMI patients undergoing primary PCI, is significantly associated with an increased risk of recurrent cardiovascular events at 6 months.
Answers are grounded in this paper and cite their sources.
Clopidogrel resistance may identify higher-risk STEMI patients after PCI; leaves open whether resistance-guided therapy improves outcomes.
BACKGROUND: Although clopidogrel reduces the risk of cardiovascular episodes after coronary events and stenting, a substantial number of incidents continue to occur. METHODS AND RESULTS: The antiplatelet effect of clopidogrel was studied prospectively in 60 consecutive patients who underwent primary angioplasty (percutaneous coronary intervention [PCI]) with stenting for acute ST-segment-elevation myocardial infarction (STEMI) to determine whether variability in response to clopidogrel affects clinical outcomes. Patients were stratified into 4 quartiles according to the percentage reduction of ADP-induced platelet aggregation. Although patients in the first quartile were resistant to the effects of clopidogrel (ADP-induced platelet aggregation at day 6, 103+/-8% of baseline), ADP-induced aggregation was reduced to 69+/-3%, 58+/-7%, and 33+/-12% of baseline, respectively, in patients in quartiles 2 through 4 (P<0.01 for all). In addition, epinephrine-induced platelet aggregation and platelet aggregation under flow conditions, assessed by the cone-and-plate(let) analyzer method, were reduced significantly less in the first quartile than in quartiles 2 through 4. Whereas 40% of patients in the first quartile sustained a recurrent cardiovascular event during a 6-month follow-up, only 1 patient (6.7%) in the second quartile and none in the third and fourth quartiles suffered a cardiovascular event (P=0.007). CONCLUSIONS: Up to 25% of STEMI patients undergoing primary PCI with stenting are resistant to clopidogrel and therefore may be at increased risk for recurrent cardiovascular events.
No takes yet. Share an insight, caveat, or question.
Matetzky et al. (2004) conducted a cohort in Acute ST-segment-elevation myocardial infarction (STEMI) (n=60). Clopidogrel resistance vs. Clopidogrel responsiveness was evaluated on Recurrent cardiovascular event (p=0.007). Clopidogrel resistance in STEMI patients undergoing primary PCI was associated with a higher rate of recurrent cardiovascular events at 6 months.
Synapse has enriched 10 related papers. Consider them for comparative context: